Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : PFE (Pfizer) How high will it go? -- Ignore unavailable to you. Want to Upgrade?

To: BigKNY3 who wrote (6423)	12/3/1998 11:45:00 AM
From: Anthony Wong	Read Replies (1) \| Respond to of 9523

BAGHDAD (AP)--The Iraqi government was reported Thursday to have approved the importation of the anti-impotence pill Viagra via the private sector. The newspaper Al-Zawra said the Health Ministry has no objection to the pill manufactured by New York-based Pfizer coming into Iraq, likely through private pharmacies and hospitals. "The blue pill is in demand by many Iraqis," the weekly quoted an unnamed ministry official as saying. He suggested prescriptions would be required. The official said the government would not bring Viagra in because it is not "a badly needed humanitarian item." Most of Iraq's food and medicine is imported under the U.N.-approved oil-for-food program, which allows Iraq to sell limited quantities of oil to buy necessities for its 22 million people. The sanctions, imposed to punish Iraq for its 1990 invasion of Kuwait, limit oil sales, ban air travel and bar most international financial transactions. Viagra is manufactured by Pfizer Inc. (PFE). (END) DOW JONES NEWS 12-03-98 11:02 AM

To: BigKNY3 who wrote (6423)	12/3/1998 8:34:00 PM
From: Anthony Wong	Read Replies (1) \| Respond to of 9523

12/03 18:41 Inhale <INHL.O> poised for profits - BusinessWeek NEW YORK, Dec 3 (Reuters) - Inhale Therapeutic Systems Inc. <INHL.O> could be poised to reap big profits and a run-up in its stock price after it brings a product to market that enables patients to inhale drugs such as insulin, the December 14 issue of BusinessWeek argues. What's more, Pfizer Inc. <PFE.N> is betting a lot of money that Inhale will succeed, the magazine's closely watched Inside Wall Street column said. Pfizer signed a pact with Germany's Hoechst Marion Rousel to build a jointly owned plant in Frankfurt, costing anywhere from $500 million to $800 million to build, to produce bulk insulin, the article said. And two companies also plan to help Inhale develop and promote inhaled insulin, the article added. "It is unusual for a big pharmaceutical house to plunk down hundreds of millions for a product still in clinical trials," the article said. An unnamed New York money manager said conservatively Inhale could stand to earn $45 million a year from the new product on a pre-tax basis, the article said. If so, Inhale's stock would be worth 45 to 50 rather than under 33 where it is trading now, according to the money manager, the article said. moneynet.com@NEWS-P2&Index=0&HeadlineURL=../News/NewsHeadlines.asp&DISABLE_FORM=&NAVSVC=News\Company